SG Americas Securities LLC Invests $179,000 in UroGen Pharma Ltd. (NASDAQ:URGN)

SG Americas Securities LLC bought a new stake in UroGen Pharma Ltd. (NASDAQ:URGN) in the third quarter, HoldingsChannel reports. The fund bought 14,062 shares of the company’s stock, valued at approximately $179,000.

Other hedge funds have also modified their holdings of the company. Wellington Management Group LLP grew its position in UroGen Pharma by 49.3% in the fourth quarter. Wellington Management Group LLP now owns 104,600 shares of the company’s stock valued at $1,569,000 after acquiring an additional 34,537 shares in the last quarter. Oak Ridge Investments LLC purchased a new position in shares of UroGen Pharma in the first quarter valued at $918,000. BNP Paribas Financial Markets grew its holdings in UroGen Pharma by 73.1% during the 1st quarter. BNP Paribas Financial Markets now owns 39,795 shares of the company’s stock valued at $597,000 after purchasing an additional 16,799 shares in the last quarter. Vanguard Group Inc. increased its stake in UroGen Pharma by 14.3% during the 1st quarter. Vanguard Group Inc. now owns 194,966 shares of the company’s stock worth $2,924,000 after buying an additional 24,367 shares during the period. Finally, Price T Rowe Associates Inc. MD purchased a new position in UroGen Pharma in the 1st quarter valued at about $4,008,000. 91.29% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

URGN has been the topic of several recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of UroGen Pharma in a research note on Tuesday, October 15th. Oppenheimer restated an “outperform” rating and issued a $40.00 price target on shares of UroGen Pharma in a research note on Wednesday, October 16th. EF Hutton Acquisition Co. I raised shares of UroGen Pharma to a “strong-buy” rating in a report on Monday, October 14th. Finally, Guggenheim assumed coverage on shares of UroGen Pharma in a research report on Thursday, August 22nd. They set a “buy” rating and a $40.00 price target on the stock. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $48.38.

UroGen Pharma Trading Down 2.7 %

NASDAQ URGN opened at $12.13 on Thursday. The company has a debt-to-equity ratio of 3.23, a quick ratio of 7.93 and a current ratio of 8.15. UroGen Pharma Ltd. has a one year low of $10.60 and a one year high of $20.70. The company has a 50-day simple moving average of $13.30 and a 200-day simple moving average of $14.32. The firm has a market capitalization of $284.45 million, a PE ratio of -3.70 and a beta of 1.11.

UroGen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Tuesday, August 13th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.09). The company had revenue of $21.85 million during the quarter, compared to analyst estimates of $23.69 million. On average, equities analysts forecast that UroGen Pharma Ltd. will post -3.49 earnings per share for the current year.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.